Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Illumina’s new NovaSeq X can sequence 20,000 genomes a year

By Sean Whooley | October 4, 2022

Illumina NovaSeq X Series genome sequencer (1)

[Image from Illumina]

Illumina (Nasdaq:ILMN) announced last week that it launched its new NovaSeq X series of production-scale sequencers.

San Diego-based Illumina said its new sequencers “push the limits of what is possible with genomic medicine.” NovaSeq X and NovaSeq X Plus offer faster, more powerful and more sustainable sequencing. The latter can generate more than 20,000 whole genomes per year.

At a clip about 2.5 times the throughput of prior sequences, this accelerates genomic discover and clinical insights, Illumina said. The company redesigned every dimension of its sequencers with what it calls revolutionary new technology to increase speed, scale, accuracy and sustainability.

The company launched a fundamentally new sequencing by synthesis (SBS) chemistry. Formerly known as Chemistry X and now called XLEAP-SBS, it engineered it for twice the speed and up to three times better accuracy.

Illumina also developed its highest-resolution optics and ultra-high-density flow cells. Those deliver 2.5-times greater throughput while driving down sequencing costs. The company integrated its on-board DRAGEN Bio-IT with ORA compression for highly accurate and fully automated secondary analysis with five times lossless data compression.

Finally, the new sequencers feature the creation of 15 new thermostable reagents. These support ambient-temperature shipping, eliminating the need for dry ice and reducing waste.

Improved health for patients and the planet

The waste and environmental impact reduction reflects Illumina’s commitment to support the health of people and the planet, the company said. It features a 90% reduction in packaging waste and weight and 50% reduction in plastic usage compared to NovaSeq 6000. The enablement of ambient-temperature shipping of reagents will result in nearly 500 tons of dry ice savings per year, while significantly reducing waste streams, Illumina added.

“Illumina has been a pioneer in genomics for more than two decades, and with this new sequencer, we are reinventing the genomics industry once again. Today, we are forging a new path forward to advance more breakthroughs in cancer and genetic disease treatments, precision therapies, and pandemic preparedness,” said Francis deSouza, Illumina’s CEO. “Innovations like NovaSeq X are at the heart of how we will transform patient lives, and this groundbreaking technology will empower researchers, scientists, and clinicians in the fight to diagnose, treat – and eventually cure – disease while making genomics more sustainable and accessible to millions more people around the world.”


Filed Under: Genomics/Proteomics
Tagged With: Illumina
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE